Small interfering RNA-mediated silencing of cytochrome P450 3A4 gene

Drug Metabolism and Disposition

Volumn 34, Issue 9, 2006, Pages 1650-1657

  Chen, Jie ^a   Yang, Xiao Xia ^b   Huang, Min ^a,d   Hu, Ze Ping ^b   He, Ming ^a,d   Duan, Wei ^c   Chan, Eli ^b   Sheu, Fwu Shan ^b   Chen, Xiao ^a   Zhou, Shu Feng ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NANCHANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; IFOSFAMIDE; NIFEDIPINE; OLIGONUCLEOTIDE; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; CELL LINE; CHINESE HAMSTER; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CALCIUM CHANNEL BLOCKERS; CELL LINE; CELL SURVIVAL; CRICETINAE; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; GENETIC VECTORS; IFOSFAMIDE; INHIBITORY CONCENTRATION 50; NIFEDIPINE; OLIGONUCLEOTIDES; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

CRICETULUS GRISEUS;

EID: 33747833709     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.009837     Document Type: Article

References (40)

1. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV, et al. (1989) Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 264:10388-10395.
2. Bernstein E, Caudy AA, Hammond SM, and Hannon GJ (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature (Lond) 409:363-366.
3. Burk O, Koch I, Raucy J, Hustert E, Eichelbaum M, Brockmoller J, Zanger UM, and Wojnowski L (2004) The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem 279:38379-38385.
4. Clayton J (2004) RNA interference: the silent treatment. Nature (Lond) 431:599-605.
5. Dorn G, Patel S, Wotherspoon G, Hemmings-Mieszczak M, Barclay J, Natt FJ, Martin P, Bevan S, Fox A, Ganju P, et al. (2004) siRNA relieves chronic neuropathic pain. Nucleic Acids Res 32:e494.
6. Engst W, Landsiedel R, Hermersdorfer H, Doehmer J, and Glatt H (1999) Benzylic hydroxylation of 1-methylpyrene and 1-ethylpyrene by human and rat cytochromes P450 individually expressed in V79 Chinese hamster cells. Carcinogenesis 20:1777-1785.
7. Fraser A (2004) RNA interference: human genes hit the big screen. Nature (Lond) 428:375-378.
8. Galetin A, Ito K, Hallifax D, and Houston JB (2005) CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 314:180-190.
9. Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M, Deglmann CJ, Burk O, Buntefuss D, Escher S, et al. (2001) Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 11:111-121.
10. Gupta S, Schoer RA, Egan JE, Hannon GJ, and Mittal V (2004) Inducible, reversible, and stable RNA interference in mammalian cells. Proc Natl Acad Sci USA 101:1927-1932.
11. Hannon GJ (2002) RNA interference. Nature (Lond) 418:244-251.
12. Jounaidi Y, Guzelian PS, Maurel P, and Vilarem MJ (1994) Sequence of the 5′-flanking region of CYP3A5: comparative analysis with CYP3A4 and CYP3A7. Biochem Biophys Res Commun 205:1741-1747.
13. Kim DH, Longo M, Han Y, Lundberg P, Cantin E, and Rossi JJ (2004) Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol 22:321-325.
14. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U, et al. (2002) Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30:1108-1114.
15. Krusekopf S, Roots I, and Kleeberg U (2003) Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43. Eur J Pharmacol 466:7-12.
16. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond) 227:680-685.
17. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
18. Marques JT and Williams BR (2005) Activation of the mammalian immune system by siRNAs. Nat Biotechnol 23:1399-1405.
19. Meister G and Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature (Lond) 431:343-349.
20. Mello CC and Conte D Jr (2004) Revealing the world of RNA interference. Nature (Lond) 431:338-342.
21. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
22. Peng FC, Chang CC, Yang CY, Edwards RJ, and Doehmer J (2006) Territrems B and C metabolism in human liver microsomes: major role of CYP3A4 and CYP3A5. Toxicology 218:172-185.
23. Peng FC, Tseng HY, Tsai JC, Lin C, and Doehmer J (2003) Role of human hepatic cytochrome P-450s in territrem A metabolism. J Toxicol Environ Health A 66:1237-1248.
24. Philip PA, Ali-Sadat S, Doehmer J, Kocarek T, Akhtar A, Lu H, and Chan KK (1999) Use of V79 cells with stably transfected cytochrome P450 cDNAs in studying the metabolism and effects of cytotoxic drugs. Cancer Chemother Pharmacol 43:59-67.
25. Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, Bennett J, and Tolentino MJ (2003) Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 9:210-216.
26. Rendic S and Di Carlo FJ (1997) Human cytochrome P450 enzyme: a status report summarizing their reactions, substrates, induction, and inhibitors. Drug Metab Rev 29:413-580.
27. Sarkar MA, Vadlamuri V, Ghosh S, and Glover DD (2003) Expression and cyclic variability of CYP3A4 and CYP3A7 isoforms in human endometrium and cervix during the menstrual cycle. Drug Metab Dispos 31:1-6.
28. Scherer LJ and Rossi JJ (2003) Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol 21:1457-1465.
29. Scherr M, Battmer K, Dallmann I, Ganser A, and Eder M (2003) Inhibition of GM-CSF receptor function by stable RNA interference in a NOD/SCID mouse hematopoietic stem cell transplantation model. Oligonucleotides 13:353-363.
30. Schneider A, Schmalix WA, Siruguri V, de Groene EM, Horbach GJ, Kleingeist B, Lang D, Bocker R, Belloc C, Beaune P, et al. (1996) Stable expression of human cytochrome P450 3A4 in conjunction with human NADPH-cytochrome P450 oxidoreductase in V79 Chinese hamster cells. Arch Biochem Biophys 332:295-304.
31. Shih PS and Huang JD (2002) Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 30:1491-1496.
32. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals. J Pharmacol Exp Ther 270:414-423.
33. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, Chen J, Shankar P, and Lieberman J (2003) RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 9:347-351.
34. Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, Wagner L, Shenmen CM, Schuler GD, Altschul SF, et al. (2002) Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci USA 99:16899-16903.
35. Tuschl T (2002) Expanding small RNA interference. Nat Biotechnol 20:446-448.
36. Wang H, Dick R, Yin H, Licad-Coles E, Kroetz DL, Szklarz G, Harlow G, Halpert JR, and Correia MA (1998) Structure-function relationships of human liver cytochromes P450 3A: aflatoxin B1 metabolism as a probe. Biochemistry 37:12536-12545.
37. Watkins PB, Wrighton SA, Maurel P, Schuetz EG, Mendez-Picon G, Parker GA, and Guzelian PS (1985) Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci USA 82:6310-6314.
38. Zhang J, Tian Q, Yung Chan S, Chuen Li S, Zhou S, Duan W, and Zhu YZ (2005) Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab Rev 37:611-703.
39. Zhang X, Shan P, Jiang D, Noble PW, Abraham NG, Kappas A, and Lee PJ (2004) Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J Biol Chem 279:10677-10684.
40. Zhou S, Paxton JW, Tingle MD, and Kestell P (2000) Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. Drug Metab Dispos 28:1449-1456.